Receptor Tyrosine Kinase Kit and Gastrointestinal Stromal Tumours: An Overview
Authors: Sartini, S.; Dario, B.; Morelli, M.; Da Settimo, F.; La Motta, C.
Source: Current Medicinal Chemistry, Volume 18, Number 19, June 2011 , pp. 2893-2903(11)
Publisher: Bentham Science Publishers
Abstract:Kit is a growth factor receptor of the type III tyrosine kinase family, whose gain-of-function mutations have been identified as driving causes of different kinds of tumours. It thus represents a viable drug target, and the development of Kit inhibitors has been shown to be a promising therapeutic concept.
This review will focus on structural and signalling properties of both wild-type and mutant Kit, as well as its role in the development of human cancers. Special attention will be dedicated to gastrointestinal stromal tumours, GISTs. Progress in research on the aetiopathogenesis of GISTs and their therapeutic approaches will be fully discussed, focusing on the latest tendencies for the treatment of these kinds of tumours.
Document Type: Research Article
Publication date: June 1, 2011
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.